Twin Tree Management’s Atara Biotherapeutics ATRA Stock Holding History

Twin Tree Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12	Closed	-$6K	–	1210
2019 Q2	$6K	Buy	+12	New	+$8.47K	﹤0.01%	1118

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Twin Tree Management's ATRA Position: Q3 2019 in Review

Twin Tree Management sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 12 shares — an estimated $6K sold.

Twin Tree Management first reported a position in ATRA in Q2 2019 and held it in 1 quarter. The position peaked at $6K in Q2 2019. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

Twin Tree Management reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
Twin Tree Management sold 12 Atara Biotherapeutics shares in Q3 2019, an estimated $6K.
Twin Tree Management first reported a position in Atara Biotherapeutics in Q2 2019 and held it in 1 quarter.
Twin Tree Management's Atara Biotherapeutics position peaked at $6K in Q2 2019.
112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Twin Tree Management's 13F filing for Q3 2019, filed 12 Nov 2019.